StreetInsider.com News Articles

Cantor Fitzgerald Starts Satellos Bioscience Inc. (MSLE) at Overweight

Wed, 11 Mar 2026 06:10:09 -0400

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Satellos Bioscience Inc. (NASDAQ: MSLE) with a Overweight rating.

For an analyst ratings summary and ratings history on Satellos Bioscience Inc. click here. For more ratings news on Satellos Bioscience Inc. click here.

Shares of Satellos Bioscience Inc. closed at $9.54 yesterday.

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Tue, 10 Mar 2026 07:00:00 -0400

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements
Greater improvements in strength observed in participants with greater baseline muscle mass, further supporting evaluation in younger ages in ongoing BASECAMP study
Proteomic analysis from the CL-101, 28-day Phase 1a/b study demonstrated reduction in established DMD biomarkers within two weeks of SAT-3247 administration
Preclinical data in facioscapulohumeral muscular dystrophy (FSHD) show enhanced muscle strength, supporting broader clinical potential of SAT-3247
Enrollment

Form 6-K Satellos Bioscience Inc. For: Mar 10

Tue, 10 Mar 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260310/26135161.html

Form 6-K Satellos Bioscience Inc. For: Mar 10

Tue, 10 Mar 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260310/26135161.html

Form 6-K Satellos Bioscience Inc. For: Mar 10

Tue, 10 Mar 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260310/26135161.html

Form 6-K Satellos Bioscience Inc. For: Feb 24

Tue, 24 Feb 2026 07:15:00 -0400
si-local-file:///var/storage/secattach/20260224/26046639.html

Form 6-K Satellos Bioscience Inc. For: Feb 24

Tue, 24 Feb 2026 07:15:00 -0400
si-local-file:///var/storage/secattach/20260224/26046639.html

Form 6-K Satellos Bioscience Inc. For: Feb 24

Tue, 24 Feb 2026 07:15:00 -0400
si-local-file:///var/storage/secattach/20260224/26046639.html

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Tue, 24 Feb 2026 07:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Tue, 24 Feb 2026 07:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Tue, 24 Feb 2026 07:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Tue, 24 Feb 2026 07:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Tue, 24 Feb 2026 07:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Tue, 24 Feb 2026 07:00:00 -0400

TORONTO--(BUSINESS WIRE)-- Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8-11 in Orlando, Florida.
Oral presentations feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult patients with Duchenne muscular dystrophy (DMD), as well as new preclinical data evaluating the impact of SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy

Form 6-K Satellos Bioscience Inc. For: Feb 19

Thu, 19 Feb 2026 11:05:00 -0400
si-local-file:///var/storage/secattach/20260219/26027888.html

Form 6-K Satellos Bioscience Inc. For: Feb 19

Thu, 19 Feb 2026 11:05:00 -0400
si-local-file:///var/storage/secattach/20260219/26027888.html

Form 6-K Satellos Bioscience Inc. For: Feb 19

Thu, 19 Feb 2026 11:05:00 -0400
si-local-file:///var/storage/secattach/20260219/26027888.html

Form 6-K Satellos Bioscience Inc. For: Feb 18

Wed, 18 Feb 2026 14:03:00 -0400
si-local-file:///var/storage/secattach/20260218/26020753.html

Form 6-K Satellos Bioscience Inc. For: Feb 18

Wed, 18 Feb 2026 14:03:00 -0400
si-local-file:///var/storage/secattach/20260218/26020753.html

Form 6-K Satellos Bioscience Inc. For: Feb 18

Wed, 18 Feb 2026 14:03:00 -0400
si-local-file:///var/storage/secattach/20260218/26020753.html